Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

Overview of attention for article published in Breast Cancer Research, June 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (59th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

patent: 1 patent

Citations

dimensions_citation: 46 Dimensions

Readers on

mendeley: 62 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 1 X post from an account with 1,129 followers.

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors | Breast Cancer Research | Full Text https://t.co/kz01qsifMs

18 Jul 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.